AMR Conference Program Posters

Poster Presentations

The conference will showcase innovative approaches to fighting AMR. Scientists from companies and academic institutions were invited to submit an abstract for a poster presentation addressing the following AMR topics:

  • Traditional and non-traditional therapeutic approaches to tackle AMR in humans and animals
  • Technologies enabling antimicrobial vaccine and drug development (i.e. preclinical platforms, drug screening technologies, techniques for resistance testing, clinical trial design, bioinformatic tools)
  • Diagnostic AMR innovations for humans and animals
  • Other AMR topics relevant for drug and diagnostics development

Posters were selected to be presented in the exhibition of the AMR Conference. Among all posters, a jury will select three winners, who will be awarded a prize of 400, 600 and 1’000 Euro, respectively, kindly sponsored by Basilea.

Please find the abstracts that were accepted for the AMR Conference 2026 below.

Diagnostics

Understanding LMIC market needs for gonorrhea diagnostics, therapeutics, and preventatives: Findings from an eight-country assessment
Stanton Hor
Clinton Health Access Initiative

1

Novel rapid microcapillary platform enables phage-host measurements alongside antimicrobial susceptibility testing
Oliver Hancox
Astratus Ltd

2

Investigation of rapid carbapenemase-producing Klebsiella pneumoniae detection using ATR-FTIR spectroscopy coupled with Microbira Advanced Analytical Platform – Infrared (MAAP-IR)
Marianne Ismail
Microbira Ltd

3

Biological therapeutics

GenX-S™: A Non-Antibiotic Therapeutic Targeting Staphylococcal Biofilms in Diabetic Foot Ulcers
Sundaram Ramasamy
Rhogenites Biotech India PVLT

4

Structural basis for antibiotics murepavadin and thanatin targeting the lipopolysaccharide insertase LptD
Philippe A. Lehner
University of Basel

5

TUNIPEPS: Hypermodified antimicrobial peptides from marine tunicates as a blueprint for next-generation therapeutics
Andras Zeke
University of Padova

6

Microdroplet arrays for directed evolution and high-throughput screening of antimicrobial peptides
Sebastian Bargfrede
ETH Zurich

7

Monoclonal antibodies targeting the fungal cell surface: next generation antifungal therapeutics
Carol Munro
Brigid Bio

8

Development of the Atrial Natriuretic Peptide as new powerful drug against Pseudomonas aeruginosa and Staphylococcus aureus resistant strain biofilms: its mechanism of action and therapeutic potential
Olivier Lesouhaitier
Hermione Therapeutics

9

Human-derived anti PcrV monoclonal antibodies protect against Pseudomonas aeruginosa in a bloodstream infection model
Alexander Simonis
University Hospital Cologne

10

High-throughput discovery of natural product antimicrobials from previously uncultured bacteria: identification of novel hits active against Mycobacterium abscessus
Mark Wilkinson
Bactobio Ltd

11

Beta-clamp targeting peptides (BTPs); antibacterial peptides with a new target and a new mode of action
Marit Otterlei
Norwegian University of Science and Technology

12

Systematic engineering of lysins yields serum resistant and in vivo active compounds towards drug-resistant Acinetobacter baumannii
Guy Hermans
Obulytix

13

Chimerophore antibiotics: Engineering intramolecular synergy to tackle antimicrobial resistance
Liz Armas Egas
ETH Zurich

14

Vaccines

Evaluation of monoclonal antibodies as potential standards for harmonisation of bacterial vaccine immunoassays
Leanne Cleaver
Medicines and Healthcare products Regulatory Agency UK

15

Preclinical evaluation of Klebsiella pneumoniae vaccine antigen candidates in a mouse model of K. pneumoniae-induced sepsis
Courteney Tunstead
University College Dublin

16

A Dual-Use Vaccine Strategy Against Pseudomonas aeruginosa
Beckie Ingram
VacTimmune

17

Phages and phage products

Systematic Combinatorial Optimization of Three-Phage Cocktails Against Multidrug-Resistant Pseudomonas aeruginosa
Meshack Omwega
Walter Reed Army Institute of Research

18

Bacteriophage-Functionalized Biocarbon Nanodots: A Novel Antimicrobial Conjugate
Anu Priya B
Mahindra University

19

Chemical Induction of Prophages as an Antimicrobial Strategy
Shubham Joge
University of Vienna

20

Understanding bacterial defence against jumbo phages to evaluate their potential in phage therapy
Marina Mahler
University of Basel

21

MHRA Initiatives for the Advancement of Regulation for Phage Therapeutics
Matthew Lamaudiere
Medicines and Healthcare products Regulatory Agency UK

22

Precision Antimicrobials: Harnessing Phages and Tailocins for AMR Control and Diagnostic Development
Belinda Loh
Fraunhofer Institute for Cell Therapy and Immunology

23

Bio‐Responsive Hydrogel for Targeted on‐Demand Release of a Phage Cocktail for Treatment of Pseudomonas aeruginosa Infection
Qun Ren
Empa, Swiss Federal Laboratories for Materials Science and Technology

24

Digital Phagogram Platform for Rapid Matching of Phages to Multidrug-Resistant Pathogens (Patent Filed)
Baptiste Bourgine
Precise Health

25

Small molecule therapeutics

Orthology- and mutational constraint-guided drug repurposing efficiently identifies narrow-spectrum inhibitor of M. tuberculosis acting through a new target
Eachan Johnson
The Francis Crick Institute

26

A New Class of Antibiotics Overcomes Multi-Drug Resistant Bacteria by Targeting Outer Layer Glycolipid Biosynthesis
Hoan Ngo
Seoul National University

27

Effects of Incentive Mechanisms on Innovation and Collaboration in the Antibiotics Market
Jan Schläfer
Karlsruhe Institute of Technology

28

Targeting Salmonella’s virulence: Inhibition of the T3SS-2 major export apparatus protein SsaV by a synthetic small molecule
Patrick Moritz
Tübingen University Hospital

29

Deciphering Host Signaling Alterations During Carbapenem-Resistant Acinetobacter baumannii Infection Using an Integrated Proteomics–Metabolomics Approach for Host-Directed Therapy
Harshala Baddi
National Institute of Pharmaceutical Education and Research, India

30

MB1: a compound targeting of Pseudomonas aeruginosa surface attachment
Han-Yi Huang
EPFL

31

Novel fragment-based antibiotics against Gram-negative WHO I pathogens
Hannelore Meyer
Technical University of Munich

32

Makromolecular prodrug nanoparticles for the treatment of intracellular persisting pathogens
Thomas Orasch
Leibniz Institute for Natural Product Research and Infection Biology

33

Perspectives from reimbursors on the requirements of an inhaled combination drug including Disperazol to improve management of Pseudomonas aeruginosa infections in Cystic Fibrosis
Michael Graz
Disperazol Pharma

34

In vitro and in vivo activity of the novel siderophore-cephalosporin AR-2126 against carbapenem-resistant Pseudomonas aeruginosa and A. baumannii
Susanne Paukner
ARIVA Med

35

Intrabacterial Delivery of Antimicrobial Agents
Jos Paulusse
University of Twente

36

EbsArgent™, a synergistic ebselen–silver combination targeting bacterial thioredoxin reductase with bactericidal activity against a wide range of multidrug-resistant bacteria
Carlos Ratia
Thioredoxin Systems

37

ZnPor (II): a novel cationic Zinc Porphyrin based anti-infective platform
Jayne Robinson
Yale University

38

Pre-Clinical Development of a Peptide Dendrimer–Chitosan Conjugate for P. aeruginosa Wound Infections
Viorica Patrulea
University of Geneva

39

Light-Controllable Nanozyme-Based Enzyme-Mimicking Microneedle Platform for Combating Skin Subdermal Infections and Inflammation
Haihan Chen
EMPA, Swiss Federal Laboratories for Materials Science and Technology

40

APC301 - The most Potent Antibiotic against MBL-producing Pathogens?
Bjørn Klem
AdjuTec Pharma

41

Novel heptapeptide analogues of teixobactin with potent antibacterial activity against pathogenic Gram-positives
Weng Chan
University of Nottingham

42

Discovery and pre-clinical development of LY256 for the treatment of Clostridioides difficile infection
Weng Chan
University of Nottingham

43

Development of a novel DprE1-targeting lead candidate for NTM-PD treatment
Shridhar Narayanan
Foundation for Neglected Disease Research

44

EbsArgent™ as a Biofilm-preventing Urinary Catheter Coating System
Enrico Wolff
Thioredoxin Systems

45

Potent bactericidal and therapeutic activities of lysocin E regarding refractory S. aureus infection
Hiroshi Hamamoto
Yamagata University

46

Multiparameter Optimization of pathoblockers targeting elastase (LasB) for the treatment of Pseudomonas aeruginosa lung infections
Andreas M. Kany
Helmholtz Institute for Pharmaceutical Research Saarland

47

Novel thiourea antibiotic against MDR Acinetobacter baumannii with in vivo activity
Alexander Titz
Helmholtz Institute for Pharmaceutical Research Saarland

48

First-in-class metalloid-based antibiotics to overcome antimicrobial resistance
Jan Romano - de Gea
EPFL

49

Inhaled AJ-099 in treatment of Mycobacteria avium complex and Pseudomonas aeruginosa pulmonary infection
Abdi Ghaffari
A&J Science Co., Ltd.

50

A first-in-class c-di-GMP signalling inhibitor potentiates polymyxin activity against multidrug-resistant Pseudomonas aeruginosa and Escherichia coli
Tim Lindsay
Veirulence Ltd.

51

First-in-class, ultra-narrow spectrum antibacterial with a novel mode of action against multidrug-resistant Neisseria gonorrhoeae
Nhung Nguyen
University of Vienna

52

Microbiology

Inhibitor Activity and Resistance Mechanism of Compound BTD7 against Mycobacterium tuberculosis
Haftay Abraha Tadesse
Mekelle University

53

Long-term host control of Salmonella after transient virulence inhibition
Alaa Alhayek
University of Basel

54

Sub-inhibitory Surfactant Combinations Drive Mechanistic Adaptation and Preclinical AMR Risk in wild-type Escherichia coli
Joseph Nzeh
Ben-Gurion University of the Negev

55

The clinical strains of Mycobacterium abscessus with the rough colony morphotype showed the increased or sustained lung bacterial burden in a mice lung infection model
Satoshi Nakagawa
Shionogi & Co., Ltd.

56

First-in-class peptides targeting a novel Streptococcus pneumoniae intervention point (Ami-AliA/AliB permease)
Lucy Hathaway
Alterbiotix

57

Staphylococcus aureus localization in infected human bones
Florian Marro
University of Basel

58

Quantitative proteome of bacterial periplasmic predation by Bdellovibrio bacteriovorus reveals a prey-lytic protease
Simona Huwiler
University of Zurich

59

Biosynthetic Potential and Antibacterial Activity of a New Streptomyces Strain from Morocco
Yousra Benghait
University Hassan II of Casablanca

60

Rv0678-dependent BTZ-043 low level resistance in M.tuberculosis – understanding how to overcome it with improved combination therapies
Susanne Mirold-Mei
LMU University Hospital Munich

61

A Nanolitre Microdroplet Array Platform for High-Throughput Antibiotic Discovery from Streptomyces
Sten Hagen
Leiden University

62

Epidemiology and clinical development

Multidrug–resistant Gram–positive cocci as etiological factors of cardiac implantable electronic devices–related infections; data from the EXTRACT registry
Danuta Łoboda
Medical University of Silesia in Katowice

63

Immune Training With Bacterial Lysates and Reduced Antibiotic Use in Children With Recurrent Respiratory Tract Infections: A Systematic Review, Meta-analysis, and Projection Model
Dominika Ambrożej
Medical University of Warsaw

64

ATHANA – Antifungal therapeutic approaches through nanoparticle-based targeting of drugs
Hans Ulrich
Leibniz Institute for Natural Product Research and Infection Biology

65

The Impact of XF-73 Nasal Gel on the Nasal Decolonisation of S. aureus and the Use of Post-Operative Anti-staphylococcal Antibiotics in Cardio-vascular Surgery Patients in a Phase 2b Study
Daniel Hynes
AMR Bio Ltd.

66

Targeted Nasal Eradication of Staphylococcus aureus Using the Recombinant Lytic Agent HY-133: A New Strategy to Address Antimicrobial Resistance
Ingrid Wanninger
HYpharm GmbH

67

Clinical Translation of an Inhaled Bismuth-Based Antibiotic Adjuvant for Drug-Resistant Pseudomonas aeruginos
Auke van Heel
Omnicin Therapeutics 

68

PK / PD

A human lung infection model for pharmacokinetics and -dynamics studies
Leoni Swart
University of Basel

69

Standardization of the COMBINE Pneumonia Model in mice with Pseudomonas aeruginosa and Klebsiella pneumoniae
Carina Vingsbo Lundberg
Statens Serum Institut

70

Assessment of feasibility of the hollow-fiber system for PKPD studies of diarylquinolines
Fernando Sanz-García
University of Zaragoza

71

Dealing with the myth of 40% T>MIC for amoxicillin clavulanate: a hollow-fiber study using clinically relevant concentrations
Fernando Sanz-García
University of Zaragoza

72

Preclinical development of vancomycin polycationic peptide conjugate (VN-R6C) with high antimicrobial activity in vitro and in vivo
Eric Mühlberg
University of Heidelberg

73

Hollow Fiber Infection Model (HFIM): Emulating human pharmacokinetics and pharmacodynamics (PK/PD) in vitro
Edgar Igor Campos-Madueno
ETH Zurich

74

Efficacy of a daptomycin-loaded nanogel in a rat model of methicillin resistant Staphylococcus epidermidis osteomyelitis
Delphine Croisier
Vivexia

75

Devices

Portable Spray Device for Rapid Deposition of Antimicrobial Polyelectrolyte Coatings
Yijie Li
Spartha Medical

76

ElastiHeal: A Next-Generation Bioactive Skin Contact Layer for Infection Control and Healing in Hard-to-Heal Wounds
Aishah Nasir
University of Nottingham

77
Back to programm